Currently, anti-CD19 CAR-T cells have demonstrated sustained remission rates in about 40% of chemotherapy-resistant DLBCL, high-grade B-cell lymphoma (HGBCL), and primary mediastinal B-cell lymphoma (PMBCL) patients who have not received previous treatment options. The gene discussed is CD19; the disease is diffuse large B-cell lymphoma.